- Home
- CNTX vs SERA Comparison
CNTX vs SERA Comparison
Compare CNTX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | SERA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.3M | 107.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTX | SERA |
|---|---|---|
| Price | $2.26 | $2.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 56.8K |
| Earning Date | 03-19-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $0.49 | $1.37 |
| 52 Week High | $2.85 | $5.23 |
Technical Indicators
Market Signals| Indicator | CNTX | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 33.01 |
| Support Level | $2.06 | $2.32 |
| Resistance Level | $2.85 | $2.93 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 57.53 | 12.77 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.